Stryker Launches Incompass Total Ankle System to Enhance Patient Care and Boost Revenue

Stryker has launched its Incompass Total Ankle System, a product designed for patients with end-stage ankle arthritis, at the American Orthopaedic Foot & Ankle Society Annual Meeting. This innovative launch could support Stryker's aim to enhance clinical performance. Over the past month, Stryker's stock gained 4%, aligning with broader market trends. The company's total shareholder return over the past five years was 96.59%. With a current share price of $392.76, there is potential for further upside if growth materializes as expected.

Stryker Corporation (NYSE: SYK) has launched its Incompass Total Ankle System at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Savannah, Georgia. The FDA-cleared system is designed for patients with end-stage ankle arthritis and introduces an innovative implant with an enhanced instrument platform. The launch is part of Stryker's ongoing efforts to enhance clinical performance and address evolving surgeon needs.

The Incompass system mimics Stryker's Infinity and Inbone designs, offering similar implant profiles, fixation, and sulcus articulation. By leveraging these legacy systems, Stryker aims to advance clinical performance and deliver meaningful value to hospitals and patients. Both legacy systems have documented five-year survival rates of 98% or higher Stryker Launches Incompass Total Ankle System at AOFAS 2025^[1].

The system provides intraoperative flexibility, allowing surgeons to adjust implant configurations in real-time to support patient-specific needs. Incompass includes 3D-printed porous metal tibial and talar components engineered to promote early bony ingrowth, often as early as four weeks Stryker Launches Incompass Total Ankle System at AOFAS 2025^[2]. This design helps reduce procedural complexity, enhance decision-making, and lower sterilization demands.

The implants were designed using SOMA, Stryker's Orthopedic Modeling and Analytics tool, which analyzed real patient anatomy from arthritic ankle CT scans in the Prophecy database. SOMA was used to study bone quality and optimize implant location. Further insights were gained from more than 80,000 Prophecy scans . The system's instrumentation was refined with input from a global clinical advisory team of experienced foot and ankle surgeons, informed by more than 100,000 total ankle cases .

Over the past month, Stryker's stock gained 4%, aligning with broader market trends. The company's total shareholder return over the past five years was 96.59%. With a current share price of $392.76, there is potential for further upside if growth materializes as expected.

Stryker's commitment to evidence-based design and long-term patient outcomes is evident in the development of the Incompass Total Ankle System. The launch at the AOFAS 2025 meeting underscores the company's dedication to innovation in the orthopedic field.

For more information, visit Booth #401 at AOFAS 2025.

References:
Stryker Launches Incompass Total Ankle System at AOFAS 2025^[1] Gagne OJ, Day J, Kim J, Caolo K, O’Malley MJ, Deland JT, Ellis SJ, Demetracopoulos CA. Midterm Survivorship of the INBONE II Total Ankle Arthroplasty. Foot & Ankle International. 2022 May;43(5):628–636. doi:10.1177/10711007211060047
Stryker Launches Incompass Total Ankle System at AOFAS 2025^[2] Early experience and patient-reported outcomes of 503 Infinity total ankle arthroplasties: A Concise Follow Up Townshend et al., Oct 2023 | The Bone & Joint Journal | Vol. 103-B, No. 7
Data on file at Stryker. Claim based on data from rabbit femur model. It is unknown how these results compare with clinical results in humans.
Based on internal data.